论文部分内容阅读
近年来随着介入放射学技术的发展,超选择性动脉内插管区域性治疗颅内恶性肿瘤包括颅内转移癌,目前已被广大患者接受.本技术不仅操作简单、创伤小,无论颅内肿瘤的部位深浅、大小、单发或多发、手术后复发及转移的病灶均适用.免疫治疗是治疗肿瘤的一项新技术,我们将免疫制剂保尔佳及化疗药物通过特殊导管直接灌注肿瘤滋养动脉内,使癌肿内的药物浓度比全身化疗时高数十倍,甚至数百倍;并能通过严格控制灌注药物的速度,使其与不同分裂期的肿瘤细胞充分接触,高效杀伤癌细胞;也为以往不能手术的患者创造再手术的机会,减少术后的复发,有效地提高中晚期颅内恶性肿瘤的治愈率.保尔佳直接抑制肿瘤细胞的糖酵解,同时增加机体免疫力,对人体无任何副作用.我们对30例原发和继发颅内恶性肿瘤进行免疫制剂和化疗药的联合应用,其中29例患者的头痛、头晕、失语、半身
In recent years, with the development of interventional radiology technology, the regional treatment of intracranial malignant tumors with intracranial malignant tumors including intracranial metastases by super selective arterial intubation has been accepted by the vast majority of patients.This technique not only has the advantages of simple operation and small trauma, Tumor site depth, size, single or multiple, postoperative recurrence and metastasis lesions are applicable.Immunotherapy is a new technology for the treatment of cancer, we will immune agents Paul good and chemotherapeutic drugs through a special catheter directly infused tumor nourishment Intra-arterial, so that the drug concentration in the cancer than the number of chemotherapy when the body several times higher, or even hundreds of times; and through the strict control of drug infusion rate, so that different cell division with full access to tumor cells and efficient killing of cancer cells ; Also for the past inoperable patients to create the chance of reoperation, reduce postoperative recurrence, effectively improve the cure rate of advanced intracranial malignant tumors. Paul good direct inhibition of tumor cell glycolysis, while increasing body immunity , No side effects on the human body.We have 30 cases of primary and secondary intracranial malignant tumor immunotherapy and chemotherapy drugs in combination, including 29 patients with headache Dizziness, aphasia, bust